NovaBridge Biosciences
NBP
$4.26
-$0.01-0.23%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 09/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 102.76% | -96.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 102.76% | -96.18% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | 102.76% | -91.96% |
| SG&A Expenses | -68.00% | 3.94% | 50.72% | -53.56% | -77.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -58.49% | 0.71% | 40.39% | -38.24% | -83.22% |
| Operating Income | 58.49% | -1.94% | -42.24% | 53.59% | 82.40% |
| Income Before Tax | 38.44% | 67.50% | -168.57% | 55.14% | 90.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.44% | 67.50% | -168.57% | 55.17% | 90.62% |
| Earnings from Discontinued Operations | -- | 106.27% | 201.34% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.65% | 85.34% | 221.82% | 55.17% | 48.98% |
| EBIT | 58.49% | -1.94% | -42.24% | 53.59% | 82.40% |
| EBITDA | 58.33% | -2.37% | -52.38% | 54.15% | 83.59% |
| EPS Basic | -121.46% | 85.01% | 225.03% | 55.39% | 49.64% |
| Normalized Basic EPS | 38.99% | 55.12% | -- | 64.32% | -- |
| EPS Diluted | -121.46% | 85.01% | 225.03% | 55.35% | 49.64% |
| Normalized Diluted EPS | 38.99% | 55.12% | -- | 64.32% | -- |
| Average Basic Shares Outstanding | 0.95% | -2.12% | -2.57% | 0.50% | 1.31% |
| Average Diluted Shares Outstanding | 0.95% | -2.12% | -2.57% | 0.50% | 1.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |